Enara Bio’s purpose is to shine a light on unconventional T cell targets to develop the next generation of cancer immunotherapies designed to treat broad patient populations. Enara’s proprietary EDAPT™ platform enables the discovery of Dark Antigens™, a novel source of shared, tumor-specific T cell targets derived from genomic dark matter. We are pioneering approaches to exploit these Dark Antigen targets with a range of immunotherapeutic modalities, including bispecific T-cell engagers, adoptive cell therapies and cancer vaccines. Based in Oxford, UK, Enara Bio is backed by RA Capital, Samsara Biocapital and SV Health Investors. For more information, please visit: www.enarabio.com Comments and DMs to this account are not monitored, for any further information please head to our website
Location: United Kingdom, England, Oxford
Employees: 11-50
Total raised: $50M
Founded date: 2016
Investors 2
| Date | Name | Website |
| - | RA Capital... | racap.com |
| - | SV Health ... | svhealthin... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 03.10.2024 | Series B | $32.5M | - |
| 05.11.2019 | Series A | $17.5M | - |
Mentions in press and media 11
| Date | Title | Description |
| 03.10.2024 | Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens® | Oxford, United Kingdom – October 3, 2024. Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. The round was co-led by new investors, Pfizer Ventu... |
| 03.10.2024 | Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens® | New investors Pfizer Ventures and M Ventures co-led the financing, with participation from all existing investors including RA Capital, Samsara BioCapital and SV Health InvestorsEnara Bio’s EDAPT® platform is pioneering the discovery of Dar... |
| 03.10.2024 | Enara Bio Raises $32.5M in Series B Financing | Enara Bio, an Oxford, UK-based biotechnology company developing cancer immunotherapies, raised $32.5M in Series B funding. The round was led by Pfizer Ventures and M Ventures with participation from all existing investors including RA Capit... |
| 04.01.2024 | Boehringer Ingelheim licenses multiple Dark Antigens® from Enara Bio to develop off-the-shelf immunotherapies for non-small cell lung cancer (NSCLC) | Oxford, UK – January 04, 2024. Enara Bio today announces that Boehringer Ingelheim has exercised its option to license a number of cancer antigens discovered and validated through the ongoing collaboration using Enara Bio’s Dark Antigen dis... |
| 28.09.2021 | Enara Bio announces the appointment of highly experienced biotech executive Dr. Robert Ang to its Board of Directors | Oxford, UK – 28th September 2021. Enara Bio, a biotechnology company advancing novel T-cell receptor (TCR) directed immunotherapies against unconventional, shared, cancer-specific antigens, announces the appointment of Dr. Robert Ang to the... |
| 12.01.2021 | Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies | January 12, 2021 04:00 AM Eastern Standard Time |
| 18.12.2020 | Immune Regulation makes Peter Greenleaf chairman and assembles a quintet of new execs; Bob Coughlin moves on from MassBio to JLL | Peter Greenleaf → In September, Immune Regulation raked in $53.4 million in a Series B for two programs in rheumatoid arthritis and asthma. This week, the British biotech has named Aurinia CEO Peter Greenleaf chairman of t... |
| 09.12.2020 | Enara Bio relocates to The Oxford Science Park's newest facility to expand R&D capabilities in the search for novel cancer immunotherapies | OXFORD, England and LONDON, Dec. 9, 2020 /PRNewswire/ -- Enara Bio, a biotechnology company leveraging its proprietary T-cell/T-cell receptor (TCR) discovery and Dark Antigen™ platforms to deliver targeted cancer immunotherapies, announces ... |
| 18.09.2020 | SV Health Investors welcomes six new Venture Partners to the Biotech team | Boston, MA & London, UK (September 18, 2020) – SV, a leading transatlantic healthcare venture capital and growth equity firm, today announces the addition of six new Venture Partners who join the SV Biotech team. |
| 03.06.2020 | Ervaxx rebrands as Enara Bio to reflect a broader emphasis on the discovery and development of novel TCR‐based cancer immunotherapies | Oxford and London, UK – 3rd June 2020. Enara Bio™ (formerly Ervaxx™), a biotechnology company leveraging its proprietary T‐cell/T‐cell receptor (TCR) discovery and Dark Antigen™ platforms to deliver targeted cancer immunotherapies, announce... |
Show more